Division of Samsung Electronics Co. Ltd.
Latest From Samsung BioLogics
Samsung Bioepis has become the first company to receive FDA approvals for biosimilars of all three first-generation anti-TNF biologics after gaining a nod for its Hadlima biosimilar adalimumab.
Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.
Data published by Biogen is a key factor in driving uptake and acceptance of its biosimilars, the firm’s head of biosimilars, Ian Henshaw, told Generics Bulletin in an exclusive interview.
After selecting the bio-health sector as one of three major industries to nurture, South Korea unveils new strategy to triple the industry’s global market share and improve regulations in line with global standards, with a focus on the pharma and medical device sectors. While industry supports the move, some uncertainties could slow the government’s efforts.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Samsung-Quintiles joint venture
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Samsung Electronics Co. Ltd.
- Senior Management
Tae Han Kim, PhD, CEO
Dongjoong Kim, CFO
- Contact Info
Phone: 2 2255 8500
300 Songdo Bio Way
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.